ARTICLE | Clinical News

Matritech preclinical data

April 24, 1995 7:00 AM UTC

NMPS (Cambridge, Mass.) reported that its monoclonal antibody reacted primarily with the nuclei of cancerous cells from 16 of 17 specimens removed from prostate cancers.

The antibody also reacted with cells believed to be precursors of the cancer, and had mild reactivity with adjacent tissue of benign prostatic hyperplasia in three of 18 samples. Mild reactivity also was present in three of 18 normal specimens adjacent to the tumor. ...